Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.52 |
| ▸ | GRM5 | P41594 | 5/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506778 | 0.87 | PDE10A (0.54) | PDE10AGRM5MAPK10HTTALDH1A1 | |
| SCHEMBL2475388 | 0.87 | PDE10A (0.59) | PDE10AGRM5HTTALDH1A1KDM4E | |
| SCHEMBL2479047 | 0.86 | PDE10A (0.65) | PDE10AGRM5NR3C2ALDH1A1KDM4E | |
| SCHEMBL2750773 | 0.86 | PDE10A (0.57) | PDE10AHTTNR3C2ALDH1A1KDM4E | |
| SCHEMBL2480701 | 0.85 | PDE10A (0.55) | PDE10AGRM5NR3C2ALDH1A1KDM4E | |
| SCHEMBL2498709 | 0.85 | PDE10A (0.55) | PDE10AHTTNR3C2ALDH1A1KDM4E | |
| SCHEMBL3505270 | 0.85 | PDE10A (0.55) | PDE10AHTTNR3C2ALDH1A1KDM4E | |
| SCHEMBL7906405 | 0.85 | PDE10A (0.54) | PDE10AHTTNR3C2ALDH1A1ELOVL1 | |
| SCHEMBL2477642 | 0.85 | PDE10A (0.55) | PDE10AGRM5NR3C2ALDH1A1KDM4E | |
| SCHEMBL2481135 | 0.84 | PDE10A (0.49) | PDE10AGRM5MAPK10HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239162-B | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | claimed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | claimed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | claimed |
| CN-102239162-A | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | claimed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | claimed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | claimed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | claimed |
| CN-102239162-B | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | disclosed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102239162-A | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152193-A1 | PYRIDAZINONES | PDE5A, PDE3A, PDE10A | PDE10A 3/4885GRM5 871/4885MAPK10 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.